Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Shire reports trial data for ADHD drug Vyvanse

Shire reports trial data for ADHD drug Vyvanse

27th May 2010

Shire has published findings from a new clinical study evaluating Vyvanse, its capsule-based treatment for attention deficit hyperactivity disorder (ADHD), among adolescents.

The phase III trial involved 309 patients aged between 13 and 17 and was aimed at gauging the safety and efficacy of Vyvanse when compared to a placebo control group.

It was found that those using the Shire drug experienced significant improvements in their ADHD symptoms compared to placebo, including inattention, hyperactivity and impulsivity.

Lead investigator Dr Ann Childress, president of the Center for Psychiatry and Behavioral Medicine in Las Vegas, said: “These results are important as we look for additional ways to effectively manage ADHD symptoms in adolescent patients.”

The treatment is also specified for treating ADHD among children and adults.

This comes in the same week that Shire presented data on another ADHD drug, Intuniv, which demonstrated its efficacy among patients aged between six and 17 when co-administered with stimulant medication.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.